AbbVie (ABBV) Capital Expenditures (2012 - 2026)

AbbVie has disclosed Capital Expenditures across 15 years of filings, most recently posting $265.0 million for Q1 2026.

• In Q1 2026, Capital Expenditures rose 12.77% year-over-year to $265.0 million; the TTM figure through Mar 2026 stood at $1.2 billion (up 22.44% YoY), while the FY2025 annual figure was $1.2 billion, up 24.64% from the prior year.
• Capital Expenditures declined to $265.0 million in Q1 2026, from $329.0 million in the prior quarter.
• Over the last five years, Capital Expenditures for ABBV reached as high as $381.0 million in Q3 2025 and fell as low as $143.0 million in Q2 2022.
• The 5-year median for Capital Expenditures is $219.0 million (2023), against an average of $230.9 million.
• Annual changes were most pronounced in 2022 — Capital Expenditures dropped 26.67% — and 2025, when it jumped 53.01%.
• A 5-year view of Capital Expenditures shows it stood at $213.0 million in 2022, then decreased by 3.76% to $205.0 million in 2023, then surged by 41.95% to $291.0 million in 2024, then advanced by 13.06% to $329.0 million in 2025, then retreated by 19.45% to $265.0 million in 2026.
• According to Business Quant data, Capital Expenditures over the past three periods registered $265.0 million, $329.0 million, and $381.0 million for Q1 2026, Q4 2025, and Q3 2025 respectively.